Literature DB >> 21380569

Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.

Ravindranath Reddy Gilibili1, Ramesh Mullangi, Nuggehally R Srinivas.   

Abstract

The intravenous pharmacokinetics data of ketorolac in mice, rats, rabbits, dogs and monkeys were assembled from literature. The relationship between the main pharmacokinetic parameters [viz., volume of distribution (V (d)) and clearance (CL)] and body weight was studied across five mammalian species, using double-logarithmic plots to predict the human pharmacokinetic parameters of CL and V (d) using simple allometry or with correction factors [maximum life span potential (MLP), brain weight, CF1 (bile flow/liver weight) and CF2 (bile flow/body weight)]. The metabolism pattern, biotransformation pathways and the predominant urinary excretion of parent and the formed metabolites of ketorolac were found to be similar amongst mice, rats, rabbits, dogs, monkeys and humans, facilitating the scaling process. The human parameter value for V (d) was predicted by simple allometric equation: 0.2481W(1.0549) (r (2) = 0.9217). The predicted V (d) value (21.92 L) is close to the reported value (17.5 L), whereas the CL was predicted by simple allometric approach or with standard correction factors viz., MLP, brain weight, CF1 and CF2. Best proximity CL value was obtained with MLP having allometric equation: 0.7126W(1.3264) (r (2) = 0.9640). The outcome of this exercise suggests that allometric scaling with suitable correction factors could potentially be used to predict the human pharmacokinetic parameters of drugs belonging to non-steroidal anti-inflammatory drugs retrospectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21380569     DOI: 10.1007/s13318-011-0029-x

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  26 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

2.  Interspecies scaling of biliary excreted drugs.

Authors:  Iftekhar Mahmood; Chandra Sahajwalla
Journal:  J Pharm Sci       Date:  2002-08       Impact factor: 3.534

3.  Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs.

Authors:  K Pasloske; R Renaud; J Burger; P Conlon
Journal:  J Vet Pharmacol Ther       Date:  1999-10       Impact factor: 1.786

4.  Allometric prediction of the human pharmacokinetic parameters for naveglitazar.

Authors:  Preeti Ahlawat; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

5.  Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance.

Authors:  I Mahmood; J D Balian
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

6.  Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.

Authors:  Venkata V Pavankuamr; C A Vinu; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

7.  Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.

Authors:  Preeti Ahlawat; Nuggehally R Srinivas
Journal:  Arzneimittelforschung       Date:  2009

8.  Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.

Authors:  P Ahlawat; N R Srinivas
Journal:  Xenobiotica       Date:  2008-11       Impact factor: 1.908

9.  Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis.

Authors:  E-I Lepist; W J Jusko
Journal:  J Vet Pharmacol Ther       Date:  2004-08       Impact factor: 1.786

10.  Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac.

Authors:  A Guzmán; F Yuste; R A Toscano; J M Young; A R Van Horn; J M Muchowski
Journal:  J Med Chem       Date:  1986-04       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.